About this episode:

A new vaccine shows 70% efficacy in preventing Lyme disease, but limitations to the clinical trials put the fate of this intervention in limbo. In this episode: Anna Durbin, an expert in experimental vaccines, explains where this vaccine shows promise, where it falls short, and what could happen next for licensing and regulation.

Guest:

Dr. Anna Durbin is a professor of International Health and the director of the Johns Hopkins Center for Immunization Research.

Host:

Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs.

Show links and related content:

• Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial—Pfizer

• Tickborne Diseases Are on the Rise—Here's What To Know—Johns Hopkins Bloomberg School of Public Health

• F.D.A. Reverses Decision and Agrees to Review Moderna's Flu Vaccine—New York Times

• It's Tick Season!—Public Health On Call (April 2025)

Transcript information:

Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.

Contact us:

Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.

Follow us:

• @‌PublicHealthPod on Bluesky

• @‌PublicHealthPod on Instagram

• @‌JohnsHopkinsSPH on Facebook

• @‌PublicHealthOnCall on YouTube

• Here's our RSS feed

Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.